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diseases, is a potent activator of Rho kinase (ROCK) signaling and of chemokine production in endo-
thelial cells. In this study, LPA activated ROCK, p38, JNK and NF-jB pathways and induced interleu-
kin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) mRNA and protein expression in human
endothelial cells. Wemapped signaling events downstream of ROCK, driving chemokine production.
In summary, MCP-1 production was partly regulated by ROCK acting upstream of p38 and JNK and
mediated downstream by NF-jB. IL-8 production was largely driven by ROCK through p38 and JNK
activation, but with no involvement of NF-jB.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Migration of inﬂammatory cells to a disease locus, is a critical
mechanism in the pathogenesis of inﬂammatory diseases. Endo-
thelial cells play an important role in the recruitment of inﬂamma-
tory cells through the induced expression of chemokines and cell
adhesion molecules. The proinﬂammatory lipid mediator, lyso-
phosphatidic acid (LPA) is elevated in multiple inﬂammatory dis-
eases and may have a role in the pathogenesis of rheumatoid
arthritis [1,2], atherosclerosis [3] and allergic asthma [4]. LPA in-
duces inﬂammatory responses in endothelial cells, such as the
over-expression of chemokines interleukin-8 (IL-8) and monocyte
chemotactic protein-1 (MCP-1) and of cell adhesion molecules
ICAM-1 and VCAM-1 [5–8]. LPA signaling is mediated by a family
of at least ﬁve closely related G protein-coupled receptors LPA1–
5 [5] and human umbilical vein endothelial cells (HUVECs) express
cell-surface LPA1 and LPA3 [6,7]. It has been proposed that LPA act-
ing through the LPA1 receptor, promotes Rho kinase (ROCK) activa-
tion [8,9].chemical Societies. Published by E
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lan).ROCK, a serine/threonine kinase, is the downstream effector
of the small Rho GTPase RhoA, and has two highly related
isoforms ROCK1 and ROCK2 [10]. Activation drives the phos-
phorylation of multiple substrates including myosin light chain
(MLC), the myosin phosphatase target subunit-1 (MYPT-1), the
ezrin/radixin/moesin (ERM) family of actin-binding proteins
[11] and the NF-jB p65 subunit [12], controlling a variety of
fundamental cellular functions such as proliferation, survival,
contraction, migration and the transcriptional regulation of gene
expression [13]. Phosphorylation and activation of NF-jB p65 is
essential for thrombin-mediated ROCK-dependent transcriptional
up-regulation of cell adhesion molecules [12]. However, little is
known about signal transduction promoted by LPA, leading to
the over-expression of IL-8 and MCP-1 in endothelial cells. In
this study we have shown the involvement of p38 MAP
kinase, c-Jun N-terminal kinase (JNK) and NF-jB pathways in
LPA-ROCK mediated synthesis of chemokines in human endothe-
lial cells.
2. Materials and methods
2.1. Reagents and chemicals
H1152P was purchased from Calbiochem (San Diego, CA). LPA
and Bay 11-7082 were obtained from BIOMOL Internationallsevier B.V. All rights reserved.
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from Sigma (St. Louis, MO). Anti-ROCK-1 and anti-ROCK-2 antibod-
ies were purchased from Bethyl laboratories (Montgomery, TX).
Anti-phospho MYPT-1 (Thr850) antibody was obtained from Milli-
pore (Bedford, MA). Anti-MYPT-1 and anti-GAPDH antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
diphospho MLC (Thr18/Ser19), anti-MLC-2, anti-phospho SAPK/
JNK (Thr183/Tyr185), anti-SAPK/JNK, anti-phospho p38 (Thr180/
Tyr182), anti-p38, anti-phospho NF-jB p65 (Ser536), anti-NF-jB
p65, anti-phospho c-Jun (Ser63), anti-c-Jun, anti-phospho MK-2
and anti-MK-2 antibodies were purchased from Cell Signaling
Technology (Beverly, MA).2.2. Cell culture
Primary HUVECs were purchased from LONZA (Basel, Switzer-
land) and cultured in EGM-2 medium (LONZA) in accordance with
the manufacturer’s instructions.
2.3. Whole cell extracts and Western blot analysis
1  106 HUVECs/well were plated in six-well tissue culture
plates. Cells were serum-starved overnight in EGM medium con-
taining 0.5% serum and pre-incubated for 1 h with indicated con-
centrations of inhibitors prior to stimulation with 50 lM LPA for
the denoted times. Gel electrophoresis and the Western blot were
performed according to a standard protocol. Brieﬂy, whole cell pro-
teins were extracted using M-PER™Mammalian Protein Extraction
Reagent (Thermo Fisher Scientiﬁc Inc.) containing Halt Protease
and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientiﬁc Inc.).
LDS Sample buffer (Invitrogen) was added prior to polyacrylamide
gel electrophoresis. Following transfer to PVDF membranes, pro-
teins were labeled with primary antibodies using the manufac-
turer’s suggested dilutions. After washing three times in 0.05%
Tween20 in TBS, labeled proteins were detected with the appropri-
ate HRP-conjugated secondary antibodies. Proteins were then visu-
alized with SuperSignal West Dura Extended Duration Substrate
(Thermo Fisher Scientiﬁc Inc.) according to the manufacturer’s
instructions.2.4. Measurement of secreted IL-8 and MCP-1
1  104 HUVECs/well were plated in 96-well tissue culture
plates. Serum-starved cells were pre-treated with inhibitors for
1 h prior to activation with 50 lM LPA for an additional 8 h. Cul-
ture supernatants were analyzed using the Meso Scale Discovery
(MSD; Gaithersburg, MD) electrochemiluminescence assay plat-
form according to the manufacturer’s instructions.Fig. 1. LPA induces IL-8 and MCP-1 secretion in HUVECs. Serum-starved HUVECs
were treated with the speciﬁed concentrations of LPA for 8 h. Cell culture
supernatants were harvested and IL-8 (A) and MCP-1 (B) levels were measured
using the Meso Scale Discovery electrochemiluminescence assay. ***P < 0.001 vs.
control (n = 4).2.5. Quantitative real-time PCR (qRT-PCR)
Total RNAs were isolated using the ABI PRISM 6100 Nucleic Acid
Prepstation and total RNA lysis reagents (Applied Biosystems, Fos-
ter City, CA), according to the manufacturer’s instructions. The
qScript™ One-Step qRT-PCR Kit (Quanta Bioscience, Gaithersburg,
MD) was used for reverse transcription and ampliﬁcation from
pre-developed TaqMan Gene Expression Assays speciﬁc to each
gene of interest. Ampliﬁed reactions were detected and quantiﬁed
on an ABI PRISM 7900 Sequence Detection System (Applied Biosys-
tems). Cycling parameters were denaturation at 50 C for 10 min
and 95 C for 10 min followed by 40 ampliﬁcation cycles of 95 C
for 15 s and 60 C for 1 min. Relative gene quantities were obtained
using the comparative cycle threshold (Ct) method after normali-
zation to human B2M gene.2.6. Statistical analysis
Results are expressed as the means and standard error of the
means (S.E.M.). Multigroup comparison was performed by one-
way analysis of variance, followed by the Newman–Keules test as
a post hoc analysis. Calculations were performed using the Graph-
Pad Prism program software (GraphPad Software, San Diego, CA).
3. Results
3.1. LPA induces IL-8 and MCP-1 secretion and activates the p38, JNK,
and NF-jB pathways in HUVECs
LPA treatment of HUVECs rapidly activated ROCK, as measured
by the phosphorylation of ROCK substrates MLC and MYPT-1, with
peak activation occurring within 5 min [14]. As shown in Fig. 1, an
8 h exposure to LPA triggered both IL-8 and MCP-1 secretion in a
concentration-dependent manner. In all subsequent studies, cells
were activated with 50 lM LPA. LPA also promoted p38 phosphor-
ylation that was evident within 10 min of exposure and maximal at
30 min before returning to baseline levels by 8 h (Fig. 2A). The p38
substrate MK-2 also showed a similar phosphorylation kinetics.
Phosphorylation of JNK and its substrate c-jun was only apparent
at 30 min and was sustained up to 2 h (Fig. 2B). NF-jB p65 phos-
phorylation was maximally maintained between 30 and 120 min
(Fig. 2C). There were no detected changes to levels of total p38,
MK-2, JNK, c-jun and NF-jB p65 (Fig. 2A–C).
3.2. Impact of pharmacologic inhibition with ROCK, p38, JNK and NF-
jB inhibitors on LPA-induced IL-8 and MCP-1 secretion in HUVECs
We examined whether ROCK signaling was involved in LPA-in-
duced IL-8 and MCP-1 secretion. The secretion of both chemokines
was inhibited in a concentration-dependent manner, by the ROCK
inhibitor H1152P (Fig. 3A and B). However, while IL-8 secretion
was abolished (Fig. 3A) MCP-1 secretion was only partially sup-
pressed (Fig. 3B) at the highest concentrations of inhibitor tested.
Other ROCK inhibitors such as Y-27632 and hydroxyfasudil also
showed similar inhibition proﬁles (data not shown). We also stud-
ied the outcomes of p38 (SB203580, 10 lM), JNK (SP600125,
10 lM) and NF-jB (Bay 11-7082, 5 lM and sulfasalazine, 30 lM)
inhibition on LPA-induced chemokine production. p38 and JNK
inhibitors individually inhibited IL-8 synthesis, but the combina-
tion showed signiﬁcant synergy in fully limiting LPA-induced IL-8
production (Fig. 3C). NF-jB inhibition had no impact on IL-8 secre-
tion (Fig. 3C). On the other hand, LPA-induced MCP-1 secretion was
signiﬁcantly inhibited by NF-jB inhibition (Fig. 3D). p38 and JNK
inhibitors once again showed signiﬁcant synergy in inhibiting
MCP-1 production (Fig. 3D). mRNA levels of IL-8 (Fig. 4A) and
Fig. 2. LPA activates p38, JNK and NF-jB pathways in HUVECs. Serum-starved
HUVECs were activated with 50 lM LPA for various times as shown. Activation of
the p38 (A), JNK (B) and NF-jB (C) pathways was analyzed byWestern blotting with
the speciﬁed phospo-speciﬁc antibodies (see Section 2.1). Blots were also probed
against the respective total proteins for normalization.
Fig. 3. Effect of ROCK, p38, JNK and NF-jB inhibitors on LPA-induced IL-8 and MCP-1
concentrations of the ROCK inhibitor H1152P (A, B) or with the p38 (SB203580, 10 lM
inhibitors (C, D) for 1 h, prior to stimulation with 50 lM LPA for an additional 8 h. IL-8
assay. *P < 0.05, ***P < 0.001 vs. LPA treatment (n = 4). ns, Not signiﬁcant.
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were activated with LPA in the absence or presence of H1152P or
Bay 11-7082. A similar correlation between mRNA and protein lev-
els was observed with the p38 and JNK inhibitors added either sep-
arately or simultaneously (data not shown).
3.3. ROCK is upstream of p38 and JNK in transmitting LPA-mediated
signals in HUVECs
To better understand the cascade of signaling events initiated
by LPA, we measured the phosphorylation status of multiple sub-
strates following pharmacologic inhibition with the aforemen-
tioned ROCK, p38, JNK and NF-jB inhibitors. The ROCK inhibitor
H1152P blocked LPA-mediated phosphorylation of ROCK sub-
strates MYPT-1 and MLC, in a dose dependent manner (Fig. 5A).
The p38, JNK and NF-jB inhibitors however had no impact on
MYPT-1 and MLC phosphorylation at all tested concentrations
(Fig. 5B). Interestingly, H1152P dose-dependently inhibited LPA-
mediated phosphorylation of p38 and its substrate MK-2 as well
as JNK and its substrate c-jun (Fig. 6A). The p38 and JNK inhibitors
selectively blocked signaling through their respective substrates
MK-2 and c-jun with no pathway crossover (Fig. 6B). The NF-jB
inhibitor had no effect on either p38 or JNK signaling (Fig. 6B).
3.4. NF-jB is downstream from ROCK, p38 and JNK in LPA-activated
HUVECs
In the ﬁnal set of experiments we investigated the inﬂuence of
ROCK, p38 and JNK inhibitors on NF-jB signaling by measuring the
phosphorylation of the p65 subunit. H1152P dose-dependently
inhibited LPA-driven phosphorylation of p65 (Fig. 7A). The p38
and JNK inhibitors individually blocked p65 phosphorylation and
showed synergy when added simultaneously (Fig. 7B).synthesis in HUVECs. Serum-starved HUVECs were pre-treated with the speciﬁed
), JNK (SP600125, 10 lM) or NF-jB (Bay 11-7082, 5 lM and sulfasalazine, 30 lM)
(A, C) and MCP-1 (B, D) production were measured using the Meso Scale Discovery
Fig. 4. Inﬂuence of ROCK and NF-jB inhibitors on LPA-induced IL-8 and MCP-1
mRNA in HUVECs. Serum-starved cells were pre-incubated for 1 h with either 1 lM
of ROCK inhibitor H1152P or with 5 lM of NF-jB inhibitor Bay 11-7082 prior to
stimulation with 50 lM LPA for an additional 8 h. IL-8 (A) and MCP-1 (B) mRNA
were measured via quantitative real-time PCR. ***P < 0.001 vs. LPA treatment
(n = 4). ns, Not signiﬁcant.
Fig. 5. p38, JNK and NF-jB inhibitors do not affect LPA-mediated ROCK signaling.
Serum-starved HUVECs were pre-incubated for 1 h with the indicated concentra-
tions of ROCK (A) or p38, JNK and NF-jB inhibitors (B) prior to incubation with
50 lM LPA for 5 min. Cell lysates were analyzed by Western blotting with the
speciﬁed phospho-speciﬁc and total antibodies.
Fig. 6. ROCK is upstream of p38 and JNK in driving LPA-mediated signaling in HUVECs. H
NF-jB (B) inhibitors (see Fig. 3 legend) for 1 h, followed by treatment with 50 lM LPA for
blotting as described in the legend to Fig. 2.
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In the present study, we applied a pharmacological approach to
dissect the signaling pathway downstream of LPA, leading to the
stimulated expression of IL-8 and MCP-1 in human endothelial
cells. LPA, a proinﬂammatory lipid mediator that is eminent in
multiple inﬂammatory diseases [1–4] has been well investigated
as an effective promoter of ROCK signaling [8,9]. Additionally, mul-
tiple studies have also linked LPA to the activation of p38 and JNK
pathways in diverse cell types [15–17]. In this study, the LPA-med-
iated activation of ROCK (5 min) [14] preceded that of p38, JNK and
NF-jB (30 min) (Fig. 2). By mapping the phosphorylation of path-
way-speciﬁc substrates following the pharmacologic inhibition of
individual pathways (Figs. 5 and 6), we assigned an upstream role
to ROCK in initiating signaling through p38 and JNK with NF-jB
being downstream of p38 and JNK. LPA has also been shown to en-
hance ERK phosphorylation in endothelial cells, a requisite for
endothelial cell migration and the proper development of blood
vessels [18]. We also observed an LPA-mediated activation of
ERK, but the speciﬁc MEK inhibitor U0126 had no inﬂuence on
IL-8 or MCP-1 production (data not shown). Moreover, while the
p38 and JNK inhibitors individually demonstrated a partial inhibi-
tion of LPA-driven IL-8 and MCP-1 secretion, the nearly complete
inhibition of this response to LPA needed the simultaneous addi-
tion of both inhibitors (Fig. 3). A similar dependence on p38 and
JNK and no requirement for ERK has been associated with the
LPA-linked migration response of glioma cells. Our studies clearly
identify ROCK activation as an early event (8 h) regulating LPA-
mediated expression of chemokines in endothelial cells. However,
Lin et al. [19] have demonstrated the involvement of IL-1b signal-
ing as a late event (12–24 h) modulating LPA-driven MCP-1 and IL-
8 secretion in endothelial cells.
Previous studies [19] have linked ROCK activation to LPA-in-
duced transcriptional up-regulation of IL-8 and MCP-1 mRNA and
protein in HUVEC. Our studies also revealed that LPA-induced
expression of IL-8 and MCP-1 were transcriptionally regulated
via ROCK activation. Transcription of the IL-8 gene can be stimu-
lated by multiple inducible transcription factors including AP-1,
C/EBP and NF-jB [20] that bind identiﬁed sequences on the IL-8
promoter. We observed no involvement of NF-jB in LPA-induced
IL-8 mRNA and protein expression. This is contrary to the observa-
tions of Lin et al. [19] who reported an inhibition of IL-8 expressionUVECs were pre-treated with either the speciﬁed doses of ROCK (A) or p38, JNK or
an additional 1 h. Activation of the p38 and JNK pathways was analyzed by Western
Fig. 7. NF-jB is downstream of ROCK, p38 and JNK in LPA-activated HUVECs.
HUVECs were pre-treated with either the indicated concentrations of ROCK (A) or
p38, JNK or NF-jB (B) inhibitors (see Fig. 3 legend) for 1 h, followed by LPA (50 lM)
treatment for an additional 30 min. Activation of NF-jB p65 was analyzed by
Western blotting of cell lysates.
Fig. 8. Regulation of LPA-mediated IL-8 and MCP-1 production in HUVECs.
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stimulated HUVEC. However the high dose (200 lM) and duration
(16 h) of inhibitor exposure may have led to secondary off-target
effects. The p38 and JNK pathways have been shown to co-opera-
tively modulate AP-1 driven transcription [21,22]. The possible
involvement of AP-1 in mediating LPA-driven IL-8 expression in
endothelial cells, needs to be examined. The MCP-1 promoter in-
cludes a distal NF-jB element as well as Sp1 and C/EBP motifs
[23–25]. The NF-jB inhibitor or the combined p38 and JNK inhib-
itors almost completely eliminated MCP-1 secretion (Fig. 3D).
However, blockade of the ROCK pathway only achieved a partial
inhibition of MCP-1 synthesis, implying that other pathways may
be operational upstream of p38, JNK and NF-jB in driving LPA-
mediated MCP-1 expression. The involvement of the RhoA/ROCK
pathway in NF-jB activation has been observed in inﬂammatory
diseases [26,27]. However, this signaling pathway is poorly under-
stood. In this study, inhibition of the ROCK pathway or the simul-
taneous blockade of p38 and JNK pathways signiﬁcantly
suppressed LPA-mediated p65 phosphorylation (Fig. 6). Our results
point to ROCK-driven p38 and JNK activation as being essential for
LPA-mediated NF-jB p65 induction in endothelial cells. This ﬁnd-
ing could provide new insight into how ROCK regulates NF-jB
signaling.
In conclusion, we have demonstrated the novel involvement of
ROCK activation in LPA-mediated stimulation of p38 and JNK sig-
naling, ultimately driving IL-8 and MCP-1 secretion in humanendothelial cells. Our results are schematically represented in
Fig. 8.
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